A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Pembrolizumab
Sponsor: Institute of Cancer Research, United Kingdom
Collaborators: National Institute for Health Research Biomedical Research Centre at the Royal Marsden / Institute of Cancer Research UK|Merck Sharp & Dohme LLC